- Home
- SWIM vs FTH Comparison
SWIM vs FTH Comparison
Compare SWIM & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.71
N/A
Current Price
$37.82
Company Overview
Basic Information| Metric | SWIM | FTH |
|---|---|---|
| Founded | 1956 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.8M | 835.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SWIM | FTH |
|---|---|---|
| Price | $6.71 | $37.82 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 750.9K | 279.9K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $545,912,000.00 | N/A |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $168.75 | ★ N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $4.64 | $17.50 |
| 52 Week High | $8.97 | $42.14 |
Technical Indicators
Market Signals| Indicator | SWIM | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 68.63 |
| Support Level | $6.23 | $31.03 |
| Resistance Level | $6.79 | N/A |
| Average True Range (ATR) | 0.30 | 2.85 |
| MACD | -0.09 | 0.52 |
| Stochastic Oscillator | 35.03 | 75.66 |
Price Performance
Historical Comparison SWIM
FTH
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.